I own PSTI but rarely post anymore
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The one thing that makes the most sense is the ability to stop a hostile takeover as they have stated. Again, authorized shares does not equal outstanding shares. This will not change the float unless they actually sell the new shares.
Top two insiders are also the largest shareholders. They sold what they could on the ATM and then ran out of shares to sell. They need the flexibility to make sure they can get the full loan. I don't like the doubling as they could have done a smaller increase like 15 million as a cushion and when the price gets to $25 then do a split. Or they could have done a share dividend (which could also happen) to give the shorts a day of reckoning.
They at least waited until they had a good reason (the loan) and were in a strong cash position. There is a difference between Authorized shares and Outstanding shares. That said, I do expect a negative reaction from the market until they give us some updates on the trials (like FDA or EU approval for a trial) or we get added to the Russell 2000 index.
Many companies in the index have lost a lot of market cap.
Would you please consider making this a sticky?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155328666
Even if we are on the backside of the pandemic virus crisis and other treatments are successful (and I hope they are), the recent exposure and $54 million dollar loan have put Pluristem Therapeutics PSTI into the drivers seat with two phase 3 trials nearing completion. If successful, what is this stock worth? We will have COVID trials and obviously the current Coronavirus COVID-19 SARS CoV-2 - 100% cure rate will probably not continue as $PSTI goes wide scale because of the often complex underlying factors that results in admission to the ICU. However, if you count the 7 patients we know about in Israel plus the one in New Jersey and then add in the 10 out of 12 that Mesoblast (MESO) has treated along with the one in Miami (that also got compassionate use using similar approach with MSC stem cells), then collectively statics start looking impressive even for such a small scale (MSC-cells 19 vs COVID-deaths 2). The amazing fact is that compassionate use is used only in the most dire ICU cases. When someone is not conscious, how can you claim any placebo effect? The future use for pneumonia and ARDS is a huge new market potential. Short sellers are spreading a lot of misinformation, so look closely into the manufacturing capabilities and strong IP with low cost of making 20 thousand doses from one placenta. Pluristem is the only really pure play as other top competitors either pay royalties, farm out manufacturing or split with partners. I do not think that vaccines will be the answer to the current situation as the virus mutates so quickly. How many people do you know who get the flu shot every year and still get the flu? Keeping people from dying is the best we can do and I believe PSTI can be one of the ways we do that as it works with other treatments as well.
I have been following Pluristem since before the were listed on the NASDAQ. They have had a lot of struggles and learned a lot along the way. After they lost the partnership with UTHR, they spent the time & major expense to create their own manufacturing 3D cell bioreactor and thawing system and made agreements with a major storage facility. After the death of one compassionate use 8 years ago (which had improved initial results), they also learned to combine cells from different placentas for improved results. Lots of time was spent choosing the optimal timing, dosage & cell culturing. Clinical trials seem to be going well, so I have high hopes. Digging up 8 year old news when they have since advanced into multiple phase 2 and phase 3 trials shows a desperate agenda driven bias.
Obviously, the Coronavirus COVID-19 (SARS-CoV-2) 100% cure rate will probably not continue as $PSTI goes wide scale as there are usually underlying factors that often result in admission to the ICU. However, if you count the 7 we know about in Israel plus the one in New Jersey and then add in the 10 out of 12 that Mesoblast has treated along with the one in Miami that also got compassionate use using similar approach with MSC cells then statics start looking quite good. The amazing fact is that compassionate use is used only in the most dire ICU cases. When someone is not conscious, you cannot claim that a placebo would have any effect. I really like the opportunity Pluristem stock offers compared to the other stem cell competition.
Just wait until the "indexs" are REQUIRED to buy $PSTI and more analysts jump on board.
$RDHL sell the news? $PSTI seems to be the only one gaining ground today.
I have been following Pluristem since before the were listed on the NASDAQ. They have had a lot of struggles and learned along the way. If I recall the timing correctly, after they lost the partnership with UTHR, they spent the time & major expense to create their own manufacturing and thawing system and made agreements with a cryo storage facility. My speculation is that they were having trouble with consistency which is why they lost the partnership and it appears that has been resolved now. After the death of the little girl 8 years ago, they also learned to combine cells from different placentas for improved results. Clinical trials seem to be going well, so I have high hopes. Digging up 8 year old news when they have since advanced into multiple phase 2 and phase 3 trials is agenda driven.
Weakness in MESO gave the opportunity to use shorts to take out stop losses IMHO
BTW https://www.zerohedge.com/geopolitical/scientists-find-more-evidence-novel-coronavirus-can-travel-air-pollution-particles
I admit that I initially read it incorrectly as it seems to have been sent to the POTUS with comments and is not a reply from him.
https://twitter.com/CovidMune scroll down - 2 hours ago
search twitter for ($PSTI OR Pluristem) with latest.
Just a few hours ago.
a little bird just tweeted...
COVID19 Clinical Trials & Research: Covidmune.com
@CovidMune
·
39m
Is $psti genius or silly?
they are injecting #stemcells into the muscle to treat #covid19
#MAGA2020
@realDonaldTrump
thank you for pushing the #fda to accelerate new treatment such as this and also $ino $mrna
#coronavirus
#covidmune
Zack's trying to take the egg off their face goes back to a "BUY" https://www.tickerreport.com/banking-finance/5457533/pluristem-therapeutics-nasdaqpsti-upgraded-to-buy-at-zacks-investment-research.html
While much progress has been made on may levels since this report (2011), it highlights many of the advantages that $PSTI has over competitors that new investors can learn about https://www.slideshare.net/pslice84/psti-needham-4411
The FDA double blind model is flawed for this reason... People who are put on a breathing machine are almost always already unconscious or put into a medical coma. How could a placebo have any effect on an unconscious person? They have no idea what the Doctors are treating them with. Placebo is barbaric under these circumstances. Do you think they guy in New Jersey was woken out of a coma to sign a release allowing him to receive PSTI PLX cells?
If you like graphics to help explain the mechanism you can start here and go through them although they may not be in order... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155175403
Hit piece by a fool. Question - why is 10 out of 12 considered so much better than 8 out of 8 success rate???
https://www.fool.com/investing/2020/04/24/heres-why-pluristem-therapeutics-jumped-over-28-to.aspx
It is twice the Market Cap of PSTI and being under $5 look for an RS or else many funds will have to sell. It also does not have the IP, manufacturing or ability to quickly scale like $PSTI. PSTI will own the EU and India market and may still be able to take some or all of the US market from Mesoblast even though MESO seems to have the inside track at the moment.
First you need to understand that it is not the COVID-19 virus that is killing people. It is the overreaction of the immune system. MESO and PSTI are using a similar approach so here is a brief scientific overview of the mechanism. https://www.biospace.com/article/preliminary-data-from-pluristem-s-plc-cell-program-is-promising-in-covid-19/
$MESO vs $PSTI This is an older snipet but is still true and even more so now that PSTI no longer has financing concerns and can rapidly scale for demand. Think what our price would be if we had MESO's market cap?
https://seekingalpha.com/article/1948831-mesoblast-is-no-match-for-pluristems-ip-and-manufacturing
I agree and I did not mention age at all. Many young people eat very poor quality food and do not have good immune systems. The point is the percentage that end up in distress is less than 10% and if the vast majority of these can be successfully treated with PLX, problem solved.
COVID-19 is not major a problem for 90% of the people - too many people with poor immune systems is the problem. This is why Pluristem $PSTI is needed. If we have a solution to the real problem then we could all go back to normal and continue to protect the most vulnerable the best we can and use PLX cells for those who need it...
"Washington Post reports that new data from New York’s largest hospital system showed that survival rates for patients placed on ventilators are even lower than previously believed. The data showed that a staggering 88% of coronavirus patients who were placed on ventilators in the state's hospitals didn’t survive. Doctors, meanwhile, are also seeing more strange complications from the disease involving blood clots and the cardiovascular system. One doctor in China who barely survived his struggle with the virus experienced an extremely strange shift in skin pigmentation."
An interesting tweet...
Grey Zone
@greyzone513
$PSTI apparently shares are now quite hard to borrow. Etrade contacted me about a great idea they had where I could earn 30% if I was willing to lend out my shares. I told them to pound sand. I don't help shorts. No liferafts on rent from Greyzone
Exposure is the key here. 2.6 million twitter followers.
Ben Shapiro just tweeted on Pluristem ($PSTI) as "cautious good news".
CLI PHASE 3 RESULTS in JULY/AUGUST !!!